A diagnosis of pleural mesothelioma is rarely straightforward. Because the disease is rare, develops slowly and produces symptoms that can resemble more common respiratory conditions, reaching a confirmed diagnosis requires a structured sequence of investigations — and, crucially, specialist input at each stage.
Dr Dionysis Papadatos-Pastos, a consultant medical oncologist specialising in thoracic cancers in London, explains how pleural mesothelioma is diagnosed, what each step involves, and why specialist assessment and multidisciplinary review are so important in ensuring accuracy and guiding treatment.
Topics Covered
Topics Covered
Topics Covered
Topics CoveredWhy Diagnosis Can Be Delayed
Pleural mesothelioma has a long latency period — symptoms typically develop 20 to 50 years after asbestos exposure. When symptoms do appear, they are often gradual in onset and non-specific: breathlessness, chest pain and persistent cough are common to many respiratory conditions, and mesothelioma may not be suspected immediately.
This means that by the time a patient is referred for specialist assessment, they may have already undergone treatment for other conditions. For individuals with a known history of asbestos exposure who develop new or unexplained respiratory symptoms, early specialist referral is particularly important.
The Diagnostic Pathway in Pleural Mesothelioma
Confirming a diagnosis of pleural mesothelioma involves several stages, typically beginning with imaging and progressing through tissue sampling and specialist review.
Step 1: Initial Imaging
The diagnostic process usually begins with a chest X-ray. While a chest X-ray is rarely sufficient to diagnose mesothelioma, it may reveal pleural thickening, pleural effusion (fluid around the lung) or other abnormalities that prompt further investigation.
The most important initial imaging investigation is a CT scan of the chest and abdomen. CT scanning provides detailed cross-sectional images of the pleura and surrounding structures, and can identify:
- pleural thickening, particularly if it is irregular, nodular or involves the mediastinal pleura
- pleural effusion
- involvement of the chest wall, diaphragm or mediastinum
- lymph node enlargement
- distant disease in the abdomen or elsewhere
A CT scan cannot confirm a diagnosis of mesothelioma on its own, but it provides essential information for planning subsequent investigations and for assessing the extent of disease.
Step 2: PET-CT Scanning
A PET-CT scan combines metabolic imaging with anatomical detail. In mesothelioma, PET-CT is used to assess disease activity and extent more precisely than CT alone, and to identify areas of increased metabolic activity that may represent active tumour.
PET-CT is particularly valuable for staging — determining how far the disease has spread — which directly influences decisions about treatment.
Step 3: MRI
Magnetic resonance imaging (MRI) provides detailed information about soft tissue involvement, including the relationship of the tumour to the diaphragm, chest wall and mediastinum. MRI is not used in every case, but it plays an important role when surgical assessment is being considered, as it helps determine whether resection is technically feasible.
Step 4: Pleural Fluid Analysis
Many patients with pleural mesothelioma have a pleural effusion — a build-up of fluid between the layers of the pleura. This fluid can be drained through a procedure called thoracocentesis, and the sample sent for cytological analysis to look for malignant cells.
While pleural fluid cytology can detect mesothelioma in some cases, it is unreliable as a standalone diagnostic tool. A negative cytology result does not exclude mesothelioma, and tissue biopsy is usually required for definitive diagnosis.
Step 5: Pleural Biopsy
Tissue biopsy is the cornerstone of mesothelioma diagnosis. Only a pathological examination of pleural tissue can confirm the diagnosis with certainty and identify the histological subtype — which has important implications for prognosis and treatment.
Thoracoscopy (Medical or Video-Assisted)
Thoracoscopy involves introducing a camera into the pleural space under sedation or general anaesthesia, allowing direct visualisation of the pleura and targeted biopsy of abnormal areas. It is the most accurate method of obtaining pleural tissue and is particularly useful when a pleural effusion is present.
Video-assisted thoracoscopic surgery (VATS) provides a more detailed surgical view and allows biopsy of areas that may not be accessible through medical thoracoscopy.
CT-Guided Needle Biopsy
In patients where thoracoscopy is not possible — for example, because the pleural space is obliterated — a CT-guided needle biopsy may be performed. This involves inserting a needle through the chest wall under CT guidance to obtain a tissue sample from an area of pleural thickening.
CT-guided biopsy is less invasive than thoracoscopy but yields smaller tissue samples, which may be insufficient for full histological and immunohistochemical analysis.
Step 6: Pathological Analysis and Immunohistochemistry
Once tissue is obtained, it is examined by a specialist pathologist. Confirming a diagnosis of mesothelioma — and distinguishing it from other pleural malignancies, including metastatic carcinoma — requires immunohistochemical staining. This involves testing the tissue with a panel of antibodies that react with specific proteins, allowing the pathologist to determine the tumour type with confidence.
There are three main histological subtypes of pleural mesothelioma:
- Epithelioid — the most common subtype, generally associated with the most favourable prognosis
- Sarcomatoid — less common, typically more aggressive
- Biphasic — contains both epithelioid and sarcomatoid components, with prognosis depending on the proportion of each
Identifying the subtype is clinically important, as it influences treatment decisions and discussions about prognosis.
Step 7: Multidisciplinary Team Review
Once all investigations are complete, the case is reviewed by a specialist multidisciplinary team (MDT). In mesothelioma, MDT review is not a formality — it is a clinically essential step, given the complexity of the disease and the range of specialist input required to make accurate and safe treatment recommendations.
A mesothelioma MDT typically includes medical oncologists, thoracic surgeons, respiratory physicians, radiologists, pathologists, specialist nurses and palliative care specialists. Each brings a different perspective, and the combined assessment is more reliable than any individual clinician’s view in isolation.
MDT discussion determines:
- whether the diagnosis is confirmed
- the histological subtype and stage of disease
- whether any further investigations are needed
- the most appropriate treatment approach
- whether surgical options should be considered
- when and how to involve palliative care
For patients treated privately, MDT input remains a fundamental part of the care pathway and is integrated into specialist consultation from the outset.
The Role of Private Specialist Care in the Diagnostic Process
For patients who have been referred with suspected mesothelioma, or who have received an initial diagnosis and want specialist review, private care offers several important advantages.
Private specialist assessment allows rapid access to a consultant with specific expertise in thoracic malignancies, dedicated time to discuss the diagnostic pathway in full, and the opportunity to ensure that all appropriate investigations have been arranged and correctly interpreted. For patients with complex or equivocal findings, a specialist review of imaging and pathology results can provide clarity that may not be available within a standard outpatient pathway.
Private patients also benefit from MDT discussion as part of their care, ensuring that treatment planning reflects the full range of available expertise.
Conclusion
Diagnosing pleural mesothelioma requires a structured and specialist-led approach — from initial imaging through to tissue biopsy, pathological analysis and multidisciplinary review. Each step builds on the last, and accuracy at every stage is essential for ensuring that subsequent treatment decisions are well-founded and appropriately tailored.
For patients with a history of asbestos exposure who develop unexplained respiratory symptoms, or for those who have received a diagnosis and want specialist input into their diagnostic or treatment pathway, Dr Papadatos-Pastos is available for private consultations at several London clinics, in person and virtually.
Support and Follow-Up Care
Dr Papadatos-Pastos and his team provide ongoing support beyond medical treatment.
Patients receive clear communication, psychological care and access to nutrition, physiotherapy and symptom-management services.
Regular follow-up ensures early detection of recurrence and long-term wellbeing.
Book a Consultation
If you or someone close to you has been diagnosed with lung cancer, early consultation with a specialist can make a real difference. Appointments are available at several London clinics.
Faq
Answers to Common Questions
Patients and families frequently ask how pleural mesothelioma is diagnosed and what to expect from the investigative process. The following answers aim to explain each step clearly.
Pleural mesothelioma is diagnosed through a combination of imaging — typically a CT scan followed in many cases by PET-CT — and tissue biopsy, usually obtained through thoracoscopy or CT-guided needle biopsy. The tissue sample is then analysed by a specialist pathologist using immunohistochemical staining to confirm the diagnosis and identify the histological subtype.
The most important initial imaging investigation is a CT scan of the chest and abdomen. PET-CT scanning is often used to provide more detailed information about disease activity and extent. MRI may also be used in selected cases, particularly when surgical options are being considered.
In the vast majority of cases, yes. While imaging and pleural fluid analysis can suggest a diagnosis, tissue biopsy and pathological examination are required to confirm mesothelioma with certainty and to identify the histological subtype, which influences treatment decisions.
Thoracoscopy involves introducing a small camera into the pleural space to visualise the pleura directly and obtain targeted tissue samples. It is the most accurate method of obtaining pleural tissue for diagnosis and is particularly useful when a pleural effusion is present.
There are three main histological subtypes: epithelioid, sarcomatoid and biphasic. The epithelioid subtype is the most common and is generally associated with a more favourable prognosis. Identifying the subtype is clinically important as it influences treatment planning.
Mesothelioma is a rare and complex disease that requires input from multiple specialists — including oncologists, surgeons, radiologists and pathologists — to ensure accurate diagnosis and safe treatment planning. MDT review brings this expertise together and ensures that decisions reflect the full clinical picture.
There is no blood test that can diagnose pleural mesothelioma. Certain blood markers — such as mesothelin — may be elevated in some patients and can be used in conjunction with other investigations, but tissue biopsy remains essential for a confirmed diagnosis.
If you have a known history of asbestos exposure and develop new or unexplained breathlessness, chest pain or persistent cough, you should seek prompt medical assessment. Early specialist referral allows investigations to be arranged without delay and ensures that mesothelioma is not overlooked as a possible cause.
